1.         Schadendorf, D., et al., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol, 2015. 33(17): p. 1889-94.

 

2.         Huang, J., et al., The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. Onco Targets Ther, 2016. 9: p. 5867-5874.

 

3.         Topalian, S.L., et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012. 366(26): p. 2443-54.

 

4.         Juergens, R.A., et al., Imaging Biomarkers in Immunotherapy. Biomark Cancer, 2016. 8(Suppl 2): p. 1-13.

 

5.         Franklin, C., et al., Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol, 2016.

 

6.         Wolchok, J.D., et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res, 2009. 15(23): p. 7412-20.

 

7.         Zago, G., et al., New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics, 2016. 10: p. 103-17.

 

8.         Hodi, F.S., et al., Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A, 2008. 105(8): p. 3005-10.

 

9.         Costa, R., et al., Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget, 2016.

 

10.       Naidoo, J., et al., Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol, 2016. 27(7): p. 1362.

 

11.       Dienstmann, R., et al., Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist, 2011. 16(12): p. 1729-40.

 

12.       Bronstein, Y., et al., Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol, 2011. 197(6): p. W992-w1000.

 

13.       Nishino, M., et al., PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res, 2016.

 

14.       Murphy, K.P., et al., New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat, 2014. 37(6): p. 351-3.

 

15.       Heinzerling, L., et al., Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 2016. 4: p. 50.

 

16.       Kaehler, K.C., et al., Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol, 2010. 37(5): p. 485-98.

 

17.       Heskamp, S., et al., Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. Cancer Res, 2015. 75(14): p. 2928-36.